Clinical Trial Update: Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ABI-007 (nab-paclitaxel) in combination with paclitaxel (Taxol) for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ABI-007 (nab-paclitaxel)
• Taxol (paclitaxel)

Snippet

Sponsor: Celgene Corporation | Conditions: Breast Neoplasms, Metastases, Neoplasm | Phase 3 | Status: COMPLETED